SCHEMBL5215600

SCHEMBL5215600

CCOC(=O)CCc1sc(N)nc1-c1ccc(Cl)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.64
ALDH1A1 P00352 8/20 0.52
GAA P10253 3/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
KDM4E B2RXH2 4/20 0.49
HSD17B10 Q99714 3/20 0.49
HPGD P15428 2/20 0.49
ALOX15 P16050 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
TSHR P16473 3/20 0.47
RAB9A P51151 2/20 0.47
NPC1 O15118 1/20 0.47
LMNA P02545 1/20 0.47
POLB P06746 1/20 0.47
PTGDR2 Q9Y5Y4 1/20 0.46
MAPK1 P28482 1/20 0.44
MAPT P10636 2/20 0.44
TRPM8 Q7Z2W7 1/20 0.44
CYP1A2 P05177 1/20 0.43
PKM P14618 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1361173 0.93 HTT (0.62) HTTALDH1A1GAASMN1; SMN2KDM4E
SCHEMBL10669061 0.88 HTT (0.60) HTTALDH1A1GAASMN1; SMN2KDM4E
SCHEMBL1362464 0.88 HTT (0.64) HTTALDH1A1GAASMN1; SMN2KDM4E
SCHEMBL5209901 0.82 HTT (0.66) HTTALDH1A1GAASMN1; SMN2KDM4E
SCHEMBL5395517 0.80 HSD17B10 (0.46) HTTALDH1A1GAASMN1; SMN2KDM4E
SCHEMBL10358652 0.79 HTT (0.61) HTTALDH1A1GAASMN1; SMN2KDM4E
SCHEMBL11161509 0.78 ALDH1A1 (0.76) HTTALDH1A1SMN1; SMN2KDM4EHSD17B10
SCHEMBL10358535 0.76 HTT (0.73) HTTALDH1A1GAASMN1; SMN2KDM4E
Carbamic Acid SCHEMBL10358650 0.76 HTT (0.64) HTTALDH1A1GAASMN1; SMN2KDM4E
SCHEMBL27995931 0.76 HTT (0.77) HTTALDH1A1GAASMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7183276-B2 Azole compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-02-27 US disclosed
US-20050090534-A1 Azole compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-04-28 US disclosed
EP-1486490-A1 AZOLE COMPOUNDS Takeda Chemical Industries, Ltd. (JP) 2004-12-15 EP disclosed
US-3933838-A ANTIINFLAMMATORY, ANTIPYRETIC, ANALGESICS, ANTIBACTERIAL, DEPRESSANTS, ANTIULCER, ANTICOUGH INSTITUTO LUSO FARMACO D'ITALIA S.R.L. (IT) 1976-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050090534-A1 Azole compounds AHR, NR0B2, NR2C2 HTT 1097/4885ALDH1A1 1651/4885GAA 4803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.